Results 171 to 180 of about 47,932 (337)
Time‐Frequency Fingerprint Analysis in SEEG Source‐Space to Identify the Epileptogenic Zone
ABSTRACT This case study highlights the application of seizure fingerprint analysis in the source‐space of stereo‐EEG (SEEG) data to accurately localize the epileptogenic zone (EZ) in patients with complex cortical malformations. A 25‐year‐old female with extensive bilateral perisylvian polymicrogyria (PMG) presented with intractable focal seizures ...
Yash Shashank Vakilna+10 more
wiley +1 more source
A new periocular dataset collected by mobile devices in unconstrained scenarios. [PDF]
Zanlorensi LA+5 more
europepmc +1 more source
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad+8 more
wiley +1 more source
Study on the Axial Compressive Behavior and Constitutive Relationship of Lightweight Mixed Ceramic Concrete. [PDF]
Huang Y+4 more
europepmc +1 more source
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester+4 more
wiley +1 more source
Ability and knowledge: from epistemic transition systems to labelled stit models. [PDF]
Kuncová A+3 more
europepmc +1 more source
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji+9 more
wiley +1 more source
Ontology-Based AI Design Patterns and Constraints in Cancer Registry Data Validation. [PDF]
Nicholson N, Giusti F, Martos C.
europepmc +1 more source